Bill Summary for H 35 (2023-2024)
Jan 30 2023
|View NCGA Bill Details||2023-2024 Session|
AN ACT EXPANDING THE STATE'S DEFINITION OF OPIOID ANTAGONIST TO INCLUDE ALL OPIOID ANTAGONISTS APPROVED BY THE FEDERAL FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF A DRUG OVERDOSE; AND TO ALLOW THE USE OF ALL SUCH FEDERAL FOOD AND DRUG-APPROVED OPIOID ANTAGONISTS IN NEEDLE AND HYPODERMIC SYRINGE EXCHANGE PROGRAMS.Intro. by Sasser, Potts, Lambeth, Paré.
|View: All Summaries for Bill||Tracking:|
As title indicates, amends GS 90-12.7(a) to change the definition of opioid antagonist from naloxone hydrochloride that is approved by the FDA for treatment of a drug overdoes to an opioid antagonist that is approved by the FDA for treatment of a drug overdose. Makes conforming changes to GS 90-113.27 by requiring that needle and hypodermic syringe exchange programs offer access to opioid antagonist (was, naloxone) kits that contain an opioid antagonist approved by FDA for the treatment of a drug overdose, or referrals to programs providing access to an opioid antagonist that is approved by the FDA for the treatment of a drug overdose. Makes additional conforming changes.